ArticleKidney international reports2026
Efficacy of Obinutuzumab for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The first-generation anti-CD20 monoclonal antibody, rituximab, has effectively reduced relapse rates in patients with frequently relapsing or steroid-dependent nephrotic syndrome (FRNS or SDNS). However, its effects are often transient, and some patients are nonresponsive. Obinutuzumab, a next-generation humanized type II anti-CD20 monoclonal antibody, demonstrates stronger and more sustained B-cell depletion than rituximab. However, clinical evidence regarding its efficacy in FRNS or SDNS remains limited. Methods: This retrospective single-center cohort study included 161 patients with FRNS or SDNS who received ≥ 1 dose of obinutuzumab and had > 3 months of follow-up at our institution. We evaluated the efficacy and safety of obinutuzumab in FRNS or SDNS by analyzing the remission, relapse, and adverse events in all enrolled patients. Results: During the follow-up period, 91.9% of patients (148/161) achieved remission following obinutuzumab infusion with a median time of 2.3 months (interquartile range [IQR]: 0.8-5.8). The median relapse-free survival (RFS) was 26.9 months (95% confidence intervals [CI]: 23.2-30.6). Significant improvements were observed in nephrotic syndrome parameters: the urine protein-to-creatinine ratio (UPCR) markedly decreased (median decreased from 5.7000 g/g to 0.1024 g/g, Conclusion: Obinutuzumab may offer a new treatment option for patients with FRNS or SDNS, providing rapid disease control, high remission rates, and durable benefits with a tolerable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.